Envestnet Asset Management Inc. Boosts Position in Genmab A/S Sponsored ADR (NASDAQ:GMAB)

Envestnet Asset Management Inc. raised its stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 1.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 736,326 shares of the company's stock after buying an additional 12,545 shares during the period. Envestnet Asset Management Inc. owned about 0.11% of Genmab A/S worth $14,417,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. DAVENPORT & Co LLC lifted its holdings in Genmab A/S by 21.1% during the first quarter. DAVENPORT & Co LLC now owns 31,679 shares of the company's stock valued at $620,000 after purchasing an additional 5,529 shares during the last quarter. Oppenheimer Asset Management Inc. grew its holdings in Genmab A/S by 20.5% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 249,468 shares of the company's stock valued at $4,885,000 after buying an additional 42,361 shares in the last quarter. Blue Trust Inc. boosted its position in shares of Genmab A/S by 169.9% in the first quarter. Blue Trust Inc. now owns 7,413 shares of the company's stock valued at $145,000 after acquiring an additional 4,666 shares during the period. QRG Capital Management Inc. lifted its stake in Genmab A/S by 213.7% in the 1st quarter. QRG Capital Management Inc. now owns 74,847 shares of the company's stock worth $1,465,000 after purchasing an additional 50,990 shares in the last quarter. Finally, Fifth Third Bancorp grew its position in shares of Genmab A/S by 16.6% during the 1st quarter. Fifth Third Bancorp now owns 42,151 shares of the company's stock valued at $825,000 after purchasing an additional 6,015 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company's stock.

Analyst Ratings Changes

A number of brokerages have issued reports on GMAB. HC Wainwright reissued a "buy" rating and issued a $37.00 price target (down previously from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. Sanford C. Bernstein downgraded Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. Wall Street Zen cut shares of Genmab A/S from a "buy" rating to a "hold" rating in a report on Sunday. Finally, Truist Financial upped their target price on shares of Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a research report on Tuesday, July 8th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $37.80.

Genmab A/S Stock Down 0.6%

Genmab A/S stock traded down $0.13 during midday trading on Friday, reaching $21.88. 837,917 shares of the stock traded hands, compared to its average volume of 1,249,735. The stock's fifty day moving average is $21.18 and its 200-day moving average is $20.78. Genmab A/S Sponsored ADR has a 12 month low of $17.24 and a 12 month high of $28.56. The stock has a market cap of $14.04 billion, a P/E ratio of 12.43, a PEG ratio of 6.65 and a beta of 0.94.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.31 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.08. Genmab A/S had a return on equity of 18.08% and a net margin of 35.11%. The firm had revenue of $715.00 million during the quarter, compared to analysts' expectations of $5.17 billion. On average, equities analysts predict that Genmab A/S Sponsored ADR will post 1.45 EPS for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.